{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T22:48:31Z","timestamp":1779230911946,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jcf.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T07:59:13Z","timestamp":1655366353000},"page":"807-810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis"],"prefix":"10.1016","volume":"21","author":[{"given":"Sufyan","family":"Shakir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Echevarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-9359","authenticated-orcid":false,"given":"Simon","family":"Doe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4591-8299","authenticated-orcid":false,"given":"Malcolm","family":"Brodlie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2370-6551","authenticated-orcid":false,"given":"Stephen J.","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2022.06.003_bib0001","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.06.003_bib0002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2022.06.003_bib0003","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jcf.2021.01.007","article-title":"Challenges in the use of highly effective modulator treatment for cystic fibrosis","volume":"20","author":"Ramos","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.06.003_bib0004","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1513\/AnnalsATS.201401-044FR","article-title":"Prevalence of gastroesophageal reflux in cystic fibrosis and implications for lung disease","volume":"11","author":"Robinson","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2022.06.003_bib0005","first-page":"1","article-title":"Cystic fibrosis foundation otolaryngology care multidisciplinary consensus recommendations","author":"Kimple","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jcf.2022.06.003_bib0006","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.06.003_bib0007","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1513\/AnnalsATS.202101-057OC","article-title":"Impact of CFTR therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient reported outcomes","volume":"19","author":"Beswick","year":"2022","journal-title":"Annals ATS"},{"key":"10.1016\/j.jcf.2022.06.003_bib0008","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s10096-014-2133-8","article-title":"Aspirated bile: a major host trigger modulating respiratory pathogen colonisation in cystic fibrosis patients","volume":"33","author":"Reen","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jcf.2022.06.003_bib0009","doi-asserted-by":"crossref","unstructured":"Al-momani H, Perry A, Stewart CJ, Jones R, Krishnan A, Robertson AG, et\u00a0al. Microbiological profiles of sputum and gastric juice aspirates in cystic fibrosis patients. Scientific Reports 6:26985 doi: 10.1038\/srep.26985.","DOI":"10.1038\/srep26985"},{"key":"10.1016\/j.jcf.2022.06.003_bib0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcf.2016.07.004","article-title":"Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation","volume":"16","author":"Zeybel","year":"2017","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.06.003_bib0011","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/alr.22251","article-title":"Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients","volume":"9","author":"McCormick","year":"2019","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"10.1016\/j.jcf.2022.06.003_bib0012","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0892-1997(02)00097-8","article-title":"Validity and reliability of the reflux symptom index (RSI)","volume":"16","author":"Belafsky","year":"2002","journal-title":"J Voice"},{"key":"10.1016\/j.jcf.2022.06.003_bib0013","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00408-010-9272-1","article-title":"Cough hypersensitivity syndrome: a distinct clinical entity","volume":"189","author":"Morice","year":"2011","journal-title":"Lung"},{"key":"10.1016\/j.jcf.2022.06.003_bib0014","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item sinonasal outcome test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"issue":"4","key":"10.1016\/j.jcf.2022.06.003_bib0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/thoraxjnl-2017-210473","article-title":"The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers","volume":"73","author":"Rowbotham","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2022.06.003_bib0016","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"204","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.06.003_bib0017","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1183\/09031936.00061811","article-title":"Anti-reflux surgery in lung transplant recipients: outcomes and effects on quality of life","volume":"39","author":"Robertson","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jcf.2022.06.003_bib0018","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Lauryn","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.jcf.2022.06.003_bib0019","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of cystic fibrosis transmembrane conductance regulator potentiator Ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2022.06.003_bib0020","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1245\/s10434-021-09752-y","article-title":"Expression and role of CFTR in human esophageal squamous cell carcinoma","volume":"28","author":"Matsumoto","year":"2021","journal-title":"Ann Surgical Oncology"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322005914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322005914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:44Z","timestamp":1761601664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322005914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1569199322005914"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.06.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor-Tezacaftor-Ivacaftor improve Gastro-Oesophageal reflux and Sinonasal symptoms in advanced cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}